Dashboard
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 22.01%
- Company has a low Debt to Equity ratio (avg) at 0 times
With a growth in Operating Profit of 51.08%, the company declared Very Positive results in Sep 26
Stock is technically in a Mildly Bullish range
High Institutional Holdings at 29.57%
Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
INR 40,964 Cr (Mid Cap)
33.00
40
0.98%
-0.11
25.99%
8.42
Total Returns (Price + Dividend) 
Latest dividend: 32.03260553129549 per share ex-dividend date: Aug-05-2026
Risk Adjusted Returns v/s 
Returns Beta
News

Ajanta Pharma Ltd. is Rated Buy by MarketsMOJO
Ajanta Pharma Ltd. is rated 'Buy' by MarketsMOJO, with this rating last updated on 31 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 November 2026, providing investors with the latest insights into its performance and outlook.
Read More
Ajanta Pharma Ltd. Rallies 5.14% and Approaches 50 DMA Resistance — A Key Technical Test Ahead
The Sensex advanced 0.66% on 26 Oct 2026, yet Ajanta Pharma Ltd. outperformed sharply with a 5.14% gain, touching an intraday high of Rs 3,450. This 3.96 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers highlights a distinctly stock-specific rally rather than a broad market lift.
Read More
Ajanta Pharma Ltd. is Rated Hold by MarketsMOJO
Ajanta Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 28 September 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 21 October 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More Announcements 
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.
18-Nov-2026 | Source : BSEThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on November 18 2026 for Aayush Agrawal trustee Aayush Agrawal Trust
Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.
17-Nov-2026 | Source : BSEThe Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on November 16 2026 for Aayush Agrawal trustee Aayush Agrawal Trust
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.
09-Nov-2026 | Source : BSEThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on November 09 2026 for Aayush Agrawal trustee Aayush Agrawal Trust
Corporate Actions 
No Upcoming Board Meetings
Ajanta Pharma Ltd. has declared 1600% dividend, ex-date: 05 Aug 26
Ajanta Pharma Ltd. has announced 2:5 stock split, ex-date: 20 Mar 15
Ajanta Pharma Ltd. has announced 1:2 bonus issue, ex-date: 22 Jun 22
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
20.6468
Held by 34 Schemes (17.95%)
Held by 273 FIIs (7.63%)
Rajesh M Agrawal, Trustee Rajesh Agrawal Trust (14.47%)
Kotak Flexicap Fund (3.22%)
6.21%
Quarterly Results Snapshot (Consolidated) - Sep'26 - YoY
YoY Growth in quarter ended Sep 2026 is 32.53% vs 14.08% in Sep 2025
YoY Growth in quarter ended Sep 2026 is 49.18% vs 20.19% in Sep 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 13.93% vs 13.76% in Sep 2024
Growth in half year ended Sep 2025 is 11.53% vs 14.58% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 15.92% vs 10.24% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 13.55% vs 13.31% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 17.31% vs 10.44% in Mar 2025
YoY Growth in year ended Mar 2026 is 14.73% vs 12.77% in Mar 2025